Mechanistic description
NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastrophe
Evidence for (4)
Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation
NMN administration in 5xFAD mice restores cerebral NAD+ levels, improves mitochondrial function, and reduces amyloid plaque burden
Human trials of NR in older adults demonstrate safe NAD+ boosting and improvements in mitochondrial biomarkers in blood
SIRT3 deacetylase activity declines in AD brain, leading to hyperacetylated SOD2 and increased oxidative stress
Evidence against (4)
NAD+ repletion in aged humans shows peripheral effects but unclear brain benefits - no direct CNS NAD+ measurement
PARP1 knockout mice show no protection against AD-like pathology - genetic deletion does not prevent amyloid deposition in APP/PS1 mice
PARP1 as primary NAD+ consumer is disputed - relative contributions of PARP1, SIRT1, SIRT2, CD38 vary by cell type
NMN supplementation studies use supraphysiological doses - mouse studies require doses unlikely achievable in humans
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 1 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.